The primary objective of the study is to evaluate the PK of digoxin administered alone and in combination with AMG 510 in healthy participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
14
Covance Clinical Research Unit, Inc
Daytona Beach, Florida, United States
Maximum Plasma Concentration (Cmax) of Digoxin Administered Alone
Time frame: Day 1
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Digoxin Administered Alone
Time frame: Day 1
AUC from Time Zero to Infinity (AUCinf) of Digoxin Administered Alone
Time frame: Day 1
Maximum Plasma Concentration (Cmax) of Digoxin Administered in Combination with AMG 510
Time frame: Day 7
AUClast of Digoxin Administered in Combination with AMG 510
Time frame: Day 7
AUCinf of Digoxin Administered in Combination with AMG 510
Time frame: Day 7
Number of Participants with an Adverse Event (AE)
Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs will be recorded as AEs.
Time frame: Day 1 to Day 13
Cmax of AMG 510 Administered in Combination with Digoxin
Time frame: Day 7
AUClast of AMG 510 Administered in Combination with Digoxin
Time frame: Day 7
AUCinf of AMG 510 Administered in Combination with Digoxin
Time frame: Day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.